N/A
N=110
An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A
Facial Rhytides
Bottom Line
View on ClinicalTrials.gov: NCT01608659 ↗Enrolled (actual)
110
Serious AEs
—
Results posted
Aug 2012
Primary outcome: Primary: Average Total Dose Per Treatment Period — 49.2; 48.1; 45.8 Units
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- botulinum toxin Type A (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Allergan
- Primary completion
- Jun 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Total Dose Per Treatment Period |
49.2; 48.1; 45.8 | — |
| SECONDARY Inter-Injection Interval Duration of Each Treatment Period |
180.3; 144.3; 176.9 | — |
| SECONDARY Percent of Subjects Reporting Satisfaction With Treatment Effects |
99.0; 33.7; 90.3 | — |
Summary
This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.
Eligibility Criteria
Inclusion Criteria
- Previously treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A preparation
- Received 2 treatment cycles wtih botulinum toxin Type A (BOTOX®) prior to at least 1 treatment with botulinum toxin Type A (Xeomin®)
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01608659). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.